omniture
德琪(浙江)医药科技有限公司 Deqi (zhejiang) Pharmaceutical Technology Co. LTD

Latest News

Antengene Provides an Update on Its Latest Developments

* Announces two new in-house discovered assets - ATG-031, a potential first-in-class anti-CD24 mo...

2021-06-18 14:10 2213

Antengene's Partner Karyopharm Therapeutics Announces Updated Data of Eltanexor in Patients with Hypomethylating Agent Refractory MDS

--Of the 15 patients evaluable for efficacy, 7 (47%) had mCR and 5 (33%) had SD for a total disease...

2021-06-09 08:00 1403

Antengene Announces Publication of Abstract on XPO1 Inhibitor Selinexor in Relapsed or Refractory Multiple Myeloma at ASCO 2021 and EHA 2021

SHANGHAI and HONG KONG, June 4, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-06-04 08:00 1665

Antengene Announces Abstracts on Twelve Clinical Studies of Selinexor Selected by EHA 2021

SHANGHAI and HONG KONG, June 2, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-06-02 08:00 1360

Antengene Announces Fifteen Clinical Studies and Results of Selinexor to be Presented at ASCO 2021

SHANGHAI and HONG KONG, June 2, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-06-02 08:00 1322

Antengene Announces First Patient Dosed in Phase I/II Trial of Eltanexor for the Treatment of Myelodysplastic Syndrome

SHANGHAI and HONG KONG, May 28, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-05-28 08:00 1700

Antengene Appoints Kathryn Gregory as Vice President and Head of Corporate Business Development

SHANGHAI and HARTFORD, Conn., May 25, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengen...

2021-05-25 08:00 1307

Antengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708 (ATG-037)

SHANGHAI and SOUTH SAN FRANCISCO, Calif., May 17, 2021 /PRNewswire/ -- Antengene Corporation Limite...

2021-05-17 20:35 1687

Antengene Announces the Completion of the Quantitative and Systems Pharmacology Modeling for ATG-101 in Preparation for First-in-Human Trial

SHANGHAI and HONG KONG, May 17, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2021-05-17 08:00 1296

Antengene Announces the IND Approval for Eltanexor in Patients with Advanced Solid Tumors in Mainland China

SHANGHAI and HONG KONG, May 14, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-05-14 08:40 1500

Antengene Announces the Completion of Its Manufacturing Center in Shaoxing to Accelerate the Commercialization of Novel Anti-Cancer Therapies

SHANGHAI and HONG KONG, May 14, 2021 /PRNewswire/ -- Today, Antengene Corporation Limited ("Antenge...

2021-05-14 08:00 2196

Antengene Announces IND Approval in China for a Global Phase III Trial of Selinexor in Advanced or Recurrent Endometrial Cancer

SHANGHAI and HONG KONG, May 13, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-05-13 08:00 1399

Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines

SHANGHAI and HONG KONG, May 6, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEH...

2021-05-06 11:28 1485

Antengene Presented Preclinical Data Demonstrating Potent Synergistic Effect of the Combination of ATG-010 (Selinexor) and ATG-008 (Onatasertib) for the Treatment of Triple-Hit DLBCL

SHANGHAI, China and GAITHERSBURG, U.S., April 13, 2021 /PRNewswire/ -- Antengene Corporation Limite...

2021-04-13 08:00 1446

Antengene Announces First Patient Dosed in Phase II Trial of ATG-008 (Onatasertib) in Patients with Advanced Solid Tumors with Specific Genetic Alterations

SHANGHAI and HONG KONG, April 12, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", ...

2021-04-12 08:00 1417

Antengene Announces NMPA Approval of IND Application for ATG-019 in Patients with Advanced Solid Tumors or Non-Hodgkin's Lymphoma

SHANGHAI and HONG KONG, April 6, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2021-04-06 08:00 7018

Antengene Announces Financial Results for Full Year 2020

SHANGHAI and HONG KONG, March 26, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" o...

2021-03-26 08:00 2174

Antengene Appoints Kevin Lynch as Chief Medical Officer

SHANGHAI, China and MELBOURNE, Australia, March 25, 2021 /PRNewswire/ -- Antengene Corporation Limi...

2021-03-25 23:26 1617

Antengene Appoints Bo Shan as Chief Scientific Officer

SHANGHAI, March 25, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK)...

2021-03-25 22:36 1533
123